140亿美元！强生拟收购Intra-Cellular

Medaverse01-13

1月13日，强生公司正在探索收购Intra-Cellular Therapies的可能性，一家专注于中枢神经系统疾病治疗的生物制药公司。此举可能是一年多来最大的生物技术交易，Intra-Cellular的市值在最近飙升后约为100亿美元。讨论仍在进行中，没有确定的交易，但此次收购可能会打破2024年重大生物技术交易的干旱。对Intra-Cellular的兴趣是在该公司上周五解决了知识产权悬而未决的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2503343364?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-13 10:50","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2503343364","market":"us","top_or_hot":-1,"title":"140亿美元！强生拟收购Intra-Cellular","media":"Medaverse","content":"<div>\n<p>1月13日，强生公司正在探索收购Intra-Cellular Therapies的可能性，一家专注于中枢神经系统疾病治疗的生物制药公司。此举可能是一年多来最大的生物技术交易，Intra-Cellular的市值在最近飙升后约为100亿美元。讨论仍在进行中，没有确定的交易，但此次收购可能会打破2024年重大生物技术交易的干旱。对Intra-Cellular的兴趣是在该公司上周五解决了知识产权悬而未决的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113105558aba88150&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>140亿美元！强生拟收购Intra-Cellular</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n140亿美元！强生拟收购Intra-Cellular\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 10:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113105558aba88150&s=b><strong>Medaverse</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月13日，强生公司正在探索收购Intra-Cellular Therapies的可能性，一家专注于中枢神经系统疾病治疗的生物制药公司。此举可能是一年多来最大的生物技术交易，Intra-Cellular的市值在最近飙升后约为100亿美元。讨论仍在进行中，没有确定的交易，但此次收购可能会打破2024年重大生物技术交易的干旱。对Intra-Cellular的兴趣是在该公司上周五解决了知识产权悬而未决的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113105558aba88150&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113105558aba88150&s=b","article_id":"2503343364","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113105558aba88150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2503343364","pubTimestamp":1736736655,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"1月13日，强生公司正在探索收购Intra-Cellular Therapies的可能性，一家专注于中枢神经系统疾病治疗的生物制药公司。此举可能是一年多来最大的生物技术交易，Intra-Cellular的市值在最近飙升后约为100亿美元。1月10日，Intra-Cellular已与Sandoz达成和解协议，解决与CAPLYTA有关的专利诉讼。根据法律规定，Intra-Cellular Therapies将向美国联邦贸易委员会和美国司法部提交协议。Intra-Cellular Therapies对其他方提起的类似专利诉讼仍在美国新泽西州地区法院等待裁决。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4504":"桥水持仓","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","BK4007":"制药","BK4550":"红杉资本持仓","BK4588":"碎股","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","ITCI":"Intra-Cellular Therapies Inc.","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4532":"文艺复兴科技持仓","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","JNJ":"强生","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"$14 billion! Johnson & Johnson plans to acquire Intra-Cellular","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1,"ITCI":0.9},"content_text":"1月13日，强生公司正在探索收购Intra-Cellular Therapies的可能性，一家专注于中枢神经系统疾病治疗的生物制药公司。此举可能是一年多来最大的生物技术交易，Intra-Cellular的市值在最近飙升后约为100亿美元。讨论仍在进行中，没有确定的交易，但此次收购可能会打破2024年重大生物技术交易的干旱。对Intra-Cellular的兴趣是在该公司上周五解决了知识产权悬而未决的问题后产生的，这可能为这笔交易铺平了道路。如果交易完成，预计交易价值约为140亿美元，这将被视为知识产权和解后的公平价格。1月10日，Intra-Cellular已与Sandoz达成和解协议，解决与CAPLYTA®（lumateperone）有关的专利诉讼。该诉讼正在美国新泽西州地区法院等待审理，起因是Sandoz向美国FDA提交了一份简化新药申请，寻求批准在美国销售类似CAPLYTA的仿制药。和解协议允许Sandoz在2040年7月1日或某些情况下更早开始销售CAPLYTA的通用版本。根据法律规定，Intra-Cellular Therapies将向美国联邦贸易委员会和美国司法部提交协议。Intra-Cellular Therapies对其他方提起的类似专利诉讼仍在美国新泽西州地区法院等待裁决。Intra-Cellular Therapies开发的抗精神病药物Caplyta（lumateperone）被批准用于治疗精神分裂症和与双相抑郁相关的抑郁发作。24Q3 Caplyta的销售额1.75 亿美元，同比增长39%。最近还向 FDA提交了Caplyta用于重度抑郁症辅助治疗的申请。Caplyta于2019年获得FDA批准，作为一种每日一次的口服治疗用于精神分裂症，并在2021年扩展到双相情感障碍抑郁的适应症。该药品的销售额稳步增长，预计今年的销售额在6.65亿至6.85亿美元之间，且最近的销售预期已被上调。基于Intra-Cellular Therapies联合创始人兼诺贝尔奖获得者Paul Greengard博士的开创性研究，公司对细胞内信号通路和靶点有了详细的了解。药物发现工作得到了CNSProfile™的补充，这是基于诺贝尔奖获得者科学的新颖专有平台。正在利用这些知识开发包括CNSProfile™在内的技术平台，用它来验证对候选药物分子的选择。关注下方公众号，带你看世界!","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503343364","isCrawlerRequest":true}